The global market for Hemoglobin A1C (HbA1C) Testing was estimated at US$1.5 Billion in 2024 and is projected to reach US$2.3 Billion by 2030, growing at a CAGR of 8.1% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Hemoglobin A1C (HbA1C) Testing market.
The importance of HbA1c testing in diabetes management cannot be overstated, as it provides comprehensive insights into how well a patient`s blood sugar levels are being managed over time. The test is typically recommended every three to six months for individuals with diabetes, but it is also used for screening and diagnosing prediabetes and diabetes in the general population. Advances in testing technology have made HbA1c tests more accurate, accessible, and convenient, with point-of-care testing devices enabling quicker results in clinical settings. Additionally, home testing kits have become available, empowering patients to monitor their condition more proactively.
The growth in the Hemoglobin A1C (HbA1c) testing market is driven by several factors. Firstly, the rising prevalence of diabetes worldwide is increasing the demand for regular HbA1c testing to manage and diagnose the condition effectively. Secondly, advancements in diagnostic technology are making HbA1c tests more accurate and accessible, enhancing their adoption in both clinical and home settings. Thirdly, the growing emphasis on preventive healthcare and early diagnosis of diabetes is driving the market for HbA1c testing as a key component of diabetes management programs. Lastly, increasing awareness and education about diabetes and its complications are encouraging more frequent and consistent testing among at-risk populations. These factors collectively ensure the continued growth and importance of the HbA1c testing market.
Global Hemoglobin A1C (HbA1c) Testing Market - Key Trends & Drivers Summarized
Hemoglobin A1C (HbA1c) testing is a crucial diagnostic tool for managing diabetes, providing a long-term indicator of blood glucose levels over the past two to three months. Unlike regular blood glucose tests that measure a snapshot of current blood sugar levels, HbA1c tests reflect the average blood glucose levels by measuring the percentage of glycated hemoglobin in the blood. This test is essential for diagnosing diabetes, assessing the effectiveness of treatment plans, and making necessary adjustments to medication or lifestyle. It helps healthcare providers and patients monitor glycemic control more effectively, thereby reducing the risk of diabetes-related complications.The importance of HbA1c testing in diabetes management cannot be overstated, as it provides comprehensive insights into how well a patient`s blood sugar levels are being managed over time. The test is typically recommended every three to six months for individuals with diabetes, but it is also used for screening and diagnosing prediabetes and diabetes in the general population. Advances in testing technology have made HbA1c tests more accurate, accessible, and convenient, with point-of-care testing devices enabling quicker results in clinical settings. Additionally, home testing kits have become available, empowering patients to monitor their condition more proactively.
The growth in the Hemoglobin A1C (HbA1c) testing market is driven by several factors. Firstly, the rising prevalence of diabetes worldwide is increasing the demand for regular HbA1c testing to manage and diagnose the condition effectively. Secondly, advancements in diagnostic technology are making HbA1c tests more accurate and accessible, enhancing their adoption in both clinical and home settings. Thirdly, the growing emphasis on preventive healthcare and early diagnosis of diabetes is driving the market for HbA1c testing as a key component of diabetes management programs. Lastly, increasing awareness and education about diabetes and its complications are encouraging more frequent and consistent testing among at-risk populations. These factors collectively ensure the continued growth and importance of the HbA1c testing market.
SCOPE OF STUDY:
The report analyzes the Hemoglobin A1C (HbA1C) Testing market in terms of units by the following Segments, and Geographic Regions/Countries:- Segments: Technology (Ion-Exchange High Performance Liquid Chromatography (HPLC), Immunoassays, Boronate Affinity Chromatography, Direct Enzymatic Assays, Other Technologies); End-Use (Hospitals & Clinics, Diagnostic Laboratories, Other End-Uses)
- Geographic Regions/Countries: World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Ion-Exchange High Performance Liquid Chromatography (HPLC) segment, which is expected to reach US$915.7 Million by 2030 with a CAGR of a 8.6%. The Immunoassays segment is also set to grow at 9.2% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $422.0 Million in 2024, and China, forecasted to grow at an impressive 10.6% CAGR to reach $274.2 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Hemoglobin A1C (HbA1C) Testing Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Hemoglobin A1C (HbA1C) Testing Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Hemoglobin A1C (HbA1C) Testing Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Abbott Laboratories, Inc., Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., ACON Laboratories, Inc., ARKRAY, Inc. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 110 companies featured in this Hemoglobin A1C (HbA1C) Testing market report include:
- Abbott Laboratories, Inc.
- Beckman Coulter, Inc.
- Bio-Rad Laboratories, Inc.
- ACON Laboratories, Inc.
- ARKRAY, Inc.
- A. Menarini Diagnostics Srl
- Apex Biotechnology Corporation
- Axis-Shield Diagnostics Ltd.
- Agappe Diagnostics Ltd.
- Biorex Diagnostics
- Boditech Med, Inc.
- Biosurfit SA
- Accruex Biomedical Pvt., Ltd.
- Ailex Technology Group Co., Ltd.
- American Screening Corporation, Inc.
This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:
- Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
- Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
- Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
- Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
- Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
- Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
- Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAJAPANCHINAFRANCEGERMANYITALYUNITED KINGDOMSPAINRUSSIAREST OF EUROPEASIA-PACIFICAUSTRALIAINDIASOUTH KOREAREST OF ASIA-PACIFICLATIN AMERICAARGENTINABRAZILMEXICOREST OF LATIN AMERICAMIDDLE EASTIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTAFRICAIV. COMPETITION
1. MARKET OVERVIEW
WORLD BRANDS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
EUROPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories, Inc.
- Beckman Coulter, Inc.
- Bio-Rad Laboratories, Inc.
- ACON Laboratories, Inc.
- ARKRAY, Inc.
- A. Menarini Diagnostics Srl
- Apex Biotechnology Corporation
- Axis-Shield Diagnostics Ltd.
- Agappe Diagnostics Ltd.
- Biorex Diagnostics
- Boditech Med, Inc.
- Biosurfit SA
- Accruex Biomedical Pvt., Ltd.
- Ailex Technology Group Co., Ltd.
- American Screening Corporation, Inc.
